Smoking Cessation in Patients with Cardiovascular Disease

Introduction to Smoking Cessation

Smoking cessation provides substantial mortality benefits for patients who have experienced a myocardial infarction, with evidence from observational studies showing that patients who stop smoking reduce their mortality in the succeeding years by at least one-third compared with those who continue to smoke 1
Smoking cessation is associated with a 36% reduction in death and 32% reduction in MI in patients with coronary artery disease, as reported by the American College of Cardiology 2

Nicotine patches are considered safe for patients with stable cardiovascular disease, including those with a history of heart failure, according to the European Heart Journal guidelines 3
NRT does not lead to an increased risk of adverse cardiovascular events in patients with a history of cardiovascular disease, as stated by the Mayo Clinic Proceedings guidelines 4
Nicotine replacement therapy (NRT), including nicotine spray, is a safe option for patients with stable coronary artery disease, with the benefits of smoking cessation far outweighing the potential risks of short-term NRT use, particularly in patients with established cardiovascular disease 5, 3, 2

Varenicline is the most effective single pharmacotherapy for smoking cessation, acting as a nicotine receptor partial agonist, reducing withdrawal symptoms while blocking effects of nicotine from cigarettes, and has been shown to be more effective than bupropion in clinical trials 2, 6
Bupropion has shown a 23% abstinence rate at one year versus 12.4% for placebo, working as an anxiolytic agent and weak inhibitor of neuronal uptake of neurotransmitters 6, 7
Combination Nicotine Replacement Therapy (NRT) combining long-acting (patch) and short-acting (lozenges) NRT provides better efficacy than single NRT 2
Varenicline is a first-line option that may be more effective than nicotine replacement therapy for patients with cardiovascular disease, with a dosing regimen and standard treatment duration of 12 weeks, as recommended by the European Society of Cardiology (ESC) 7, 6, 8
Bupropion is an effective option with relatively few cardiovascular adverse effects, with a dosing regimen of 150-300 mg daily and demonstrated effectiveness of 23% abstinence rate at one year 7, 6

The Mayo Clinic Proceedings guidelines suggest considering adding short-acting NRT (gum or lozenge) for breakthrough cravings if needed, in addition to nicotine patches 4
Combination therapy with varenicline plus NRT lozenges has shown improved self-reported abstinence compared to varenicline alone without compromising safety, addressing both the psychological and physical aspects of nicotine addiction 2
Consider combination therapy with long-acting NRT (patch) plus short-acting NRT (spray) for better efficacy, as recommended by the American College of Cardiology 2

The American Heart Association recommends starting with appropriate dosing based on smoking habits, with a 21 mg patch for patients who smoke >10 cigarettes per day and a 14 mg patch for patients who smoke <10 cigarettes per day, as published in Circulation 9

Some patients may benefit from longer NRT treatment (>14 weeks) for successful smoking cessation, according to the Mayo Clinic Proceedings guidelines 4
The standard treatment duration for smoking cessation therapy is 12 weeks, with follow-up visits scheduled within 1-2 weeks of quit date to assess for withdrawal symptoms and medication side effects 2

Counseling intensity matters, with more intensive behavioral therapy being more effective, and should begin during hospitalization and continue after discharge, including family members, especially those who smoke, as recommended by the American Heart Association 6, 10
Failing to address environmental tobacco exposure, advising patients to avoid secondhand smoke at home and work, is a critical aspect of smoking cessation, as recommended by the American Heart Association 7, 6
Neglecting behavioral support, as pharmacotherapy alone is less effective than combined approaches, is a common pitfall to avoid, with guidance from the American Heart Association 7, 6
Use the 5 A's approach at every visit: ask about tobacco use, advise to quit, assess willingness to quit, assist with quitting, and arrange follow-up, as recommended by the American Heart Association 7, 6

Monitor for cardiovascular symptoms during therapy, though clinical trials suggest minimal risk, and assess nicotine dependence using the Fagerström test to guide appropriate dosing, as recommended by the European Heart Journal 2, 3
Schedule follow-up within 1-2 weeks of quit date to assess for withdrawal symptoms, medication side effects, and monitor chest pain symptoms and cardiovascular status, with guidance from the American Heart Association 7, 6

Be cautious with e-cigarettes, as while they may aid cessation, the risk of sustained use and unknown long-term safety may outweigh benefits, as recommended by the American College of Cardiology 2
Avoid underdosing, as inadequate nicotine replacement can lead to withdrawal symptoms and relapse, and monitor for dependence, while less common than with cigarettes, dependence on nicotine spray can occur, as reported by the American College of Cardiology 11
Referring patients to cardiac rehabilitation programs that include smoking cessation is recommended, as well as considering specialized smoking cessation programs for more intensive support 7, 6